BioDelivery Sciences (BDSI) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
BioDelivery Sciences Provides Corporate Update and Reports First Quarter 2016 Financial Results
May 10, 2016 7:00 AM EDTRALEIGH, N.C., May 10, 2016 /PRNewswire/ --
Strategic initiatives implemented to better align BUNAVAIL® expenses with revenue as part of ongoing efforts to preserve and enhance long-term value; changes expected to result in savings of approximately $20 million through 2017 BUNAVAIL prescriptions increase 180% compared to first quarter of 2015; over 350 new prescribers added in first quarter of 2016 BUNAVAIL net revenue increased 41% in first quarter compared to fourth quarter 2015 BUNAVAIL revenue per prescription increased more than 20% in the first quarter compared to fourth quarter 2015 Strong cash position of $69.4... More